These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30340600)

  • 1. Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients.
    Petrizzo A; Tagliamonte M; Mauriello A; Costa V; Aprile M; Esposito R; Caporale A; Luciano A; Arra C; Tornesello ML; Buonaguro FM; Buonaguro L
    J Transl Med; 2018 Oct; 16(1):286. PubMed ID: 30340600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
    Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
    Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
    Mukaida N; Nakamoto Y
    World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
    Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in hepatocellular carcinoma.
    Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
    Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy.
    Mauriello A; Zeuli R; Cavalluzzo B; Petrizzo A; Tornesello ML; Buonaguro FM; Ceccarelli M; Tagliamonte M; Buonaguro L
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
    Ward JP; Gubin MM; Schreiber RD
    Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.
    Yang H; Sun L; Guan A; Yin H; Liu M; Mao X; Xu H; Zhao H; Lu X; Sang X; Zhong S; Chen Q; Mao Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):667-677. PubMed ID: 32876735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver.
    Young KC; Lin PW; Hsiao WC; Chang TT; Chang YC; Wu HL
    J Med Virol; 2002 Oct; 68(2):188-96. PubMed ID: 12210407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigens as potential vaccines in hepatocellular carcinoma.
    Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.
    Yan Y; Liu N; Lu L; Zang CM; Shao B; Li Y; Wen Y; Wei Y; Cheng P
    Oncol Rep; 2013 Aug; 30(2):993-9. PubMed ID: 23754319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in cancer vaccine development for hepatocellular carcinoma.
    Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication.
    Nishida N; Kudo M
    Oncology; 2017; 92 Suppl 1():40-49. PubMed ID: 27764823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
    Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD
    Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.